The future of radiotherapy and chemotherapy in head and neck cancer
Keyword(s):
Stage I
◽
For the 40 per cent of patients with head and neck cancer who present with stage I and II disease either radiotherapy or surgery can be curative. The remaining 60 per cent have advanced loco-regional disease and even when treated with surgery and radiotherapy the five-year survival is less than 30 per cent. Most patients with relapse have loco-regional disease and second primary tumours have an incidence of three per cent a year.1 Current attempts to improve prognosis include the addition of chemotherapy, the use of brachytherapy and accelerated radiotherapy regimes such as continuous hyperfractionated accelerated radiotherapy (CHART).
1994 ◽
Vol 30
(6)
◽
pp. 367-368
◽
Keyword(s):
2011 ◽
Vol 93
(8)
◽
pp. 576-582
◽
Keyword(s):
1994 ◽
Vol 86
(23)
◽
pp. 1799-1801
◽
Keyword(s):
1997 ◽
Vol 23
(6)
◽
pp. 503-508
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 67
(3)
◽
pp. 123-129
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 96
(4)
◽
pp. 808-819
◽
Impact of second primary esophageal or lung cancer on survival of patients with head and neck cancer
2010 ◽
Vol 46
(4)
◽
pp. 249-254
◽
Keyword(s):